Chinese authorities have detained five current and former employees of AstraZeneca's oncology division in connection with alleged breaches of data privacy laws and the importation of an unapproved liver cancer drug. All the detained individuals are Chinese citizens, and the investigation is part of a broader anti-corruption campaign by the Chinese government targeting the pharmaceutical sector. AstraZeneca has acknowledged the detentions but provided no further details. The company employs around 16,000 people in China, which accounts for 13% of its global revenue. AstraZeneca's shares fell by over 3% following the news.